Envista Holdings Co. (NYSE:NVST – Get Rating) received a consensus “moderate buy” recommendation from the eight analysts who cover the company, MarketBeat.com reports. One equity research analyst gave the stock a hold rating and four gave the company a buy rating. The 1-year average price target among brokers who have reported on the stock in the past year is $46.17.
NVST has been the subject of several research analyst reports. Piper Sandler lowered its price target on Envista from $46.00 to $44.00 and set an “overweight” rating for the company in a report on Friday. William Blair reaffirmed an “outperforming” rating on Envista shares in a research note on Thursday. Goldman Sachs Group cut its price target on Envista shares from $58.00 to $45.00 and set a “buy” rating on the stock in a Thursday, July 21 research report. Evercore ISI lowered its target price on Envista shares to $44.00 in a Tuesday, August 9 research report. Finally, Morgan Stanley cut its price target on Envista shares from $49.00 to $48.00 and set an “overweight” rating on the stock in a Thursday, Oct. 13 research note.
Envista trades up 3.1%
NVST stock opened at $34.40 on Friday. The company has a debt ratio of 0.22, a quick ratio of 0.88 and a current ratio of 1.11. Envista has a one-year low of $31.67 and a one-year high of $52.03. The company’s 50-day moving average price is $34.48 and its two-hundred-day moving average price is $38.28. The company has a market capitalization of $5.62 billion, a PE ratio of 24.06, a growth price-earnings ratio of 1.40 and a beta of 1.45.
Envista (NYSE:NVST – Get Rating) last released its quarterly results on Wednesday, August 3. The company reported earnings per share (EPS) of $0.48 for the quarter, beating the consensus estimate of $0.46 by $0.02. The company posted revenue of $645.80 million for the quarter, versus analyst estimates of $657.55 million. Envista had a return on equity of 8.26% and a net margin of 11.86%. As a group, analysts predict Envista will post 1.97 earnings per share for the current fiscal year.
Institutional entries and exits
A number of large investors have recently bought and sold shares of the company. Massachusetts Financial Services Co. MA increased its holdings in Envista by 32.9% in the second quarter. Massachusetts Financial Services Co. MA now owns 10,472,153 shares of the company worth $403,598,000 after acquiring 2,594,861 additional shares last quarter. Pendal Group Ltd increased its stake in Envista by 4,842.8% in Q3. Pendal Group Ltd now owns 2,261,295 shares in the company worth $74,193,000 after buying an additional 2,215,546 shares last quarter. Artisan Partners Limited Partnership increased its stake in Envista by 66.9% during the 2nd quarter. Artisan Partners Limited Partnership now owns 5,237,560 shares of the company valued at $201,856,000 after purchasing an additional 2,099,112 shares last quarter. Jennison Associates LLC increased its stake in Envista by 191.3% during the 1st quarter. Jennison Associates LLC now owns 1,823,357 shares of the company valued at $88,816,000 after purchasing an additional 1,197,432 shares last quarter. Finally, Millennium Management LLC increased its holdings of Envista shares by 52.0% during the second quarter. Millennium Management LLC now owns 2,529,309 shares of the company valued at $97,480,000 after purchasing an additional 864,829 shares in the last quarter.
(Get a rating)
Envista Holdings Corporation, together with its subsidiaries, engages in the development, sale and marketing of dental products in the United States, China and internationally. The Company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The Company’s Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials and prefabricated and custom prostheses to oral surgeons, prosthodontists and periodontists under the Nobel Biocare, Alpha-Bio brand names. Tec, Implant Direct, Nobel Procera and orascoptic brands; and brackets and wires, tubes and bands, arches, clear aligners, digital orthodontic treatments, retainers and other orthodontic laboratory products under the Damon, Insignia, AOA and Spark brands.
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider Envista, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Envista wasn’t on the list.
Although Envista currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here